Datamonitor Healthcare
Reimbursement and Payer Management of Immune Checkpoint Inhibitors
21 Aug 2019
As immune checkpoint inhibitors continue to gain approvals in expanded patient populations, payers express concern surrounding the potential budget impact of the drug class. Considering the high costs of these treatments in comparison to standard chemotherapy, HTA and reimbursement agencies stress the requirement for solid survival data and highlight that price will be a major factor during negotiations
Request a live demo
How can we help you?
Pharma Report Store